Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand

A large-scale SARS-CoV-2 serosurvey of New Zealand blood donors (n=9806) was conducted at the end of 2020. Seroprevalence, after adjusting for test sensitivity and specificity, was very low (0.1%). This finding is consistent with limited community transmission and provides robust evidence to support New Zealand s successful elimination strategy for COVID-19.